BIA blog | CJEU decision denies SPCs for new formulations

The latest decision concerning Supplementary Protection Certificates (SPCs) was handed down by the CJEU in the Abraxis Bioscience case (C-443/17) on 21 March. The BIA’s IP Advisory Committee (IPAC) provided informal views on behalf of the sector to the UK Intellectual Protection Office (IPO) regarding this case, to inform the UK Government’s representations to the CJEU. Andrew Hutchinson of Simmons & Simmons and a member of IPAC has provided the following analysis for BIA members.

 

This decision comes after the Advocate General’s opinion at the end of 2018, which the CJEU only partially follows but with a similar outcome in applying a narrow approach to interpreting the SPC Regulation (EC/469/2009). The key headlines are:

 

  • Marketing authorisations for “new formulations” of ‘old’ active ingredients cannot qualify as “first marketing authorisations” under the SPC Regulation (under Articles 3(b) or (d));
  • Unlike the Advocate General, the CJEU did not go so far as to overrule its judgment in a previous case - Neurim (C-130/11); and
  • The CJEU does not state that Neurim was limited to its facts (i.e. veterinary-to-human species switch in re-developing an existing drug (in that case melatonin)), but the reasoning indicates that the direction of travel is a narrow approach.

Overall, the key take-home is that the CJEU have adopted a narrow approach to Article 3(d) of the SPC Regulation, which curtails the scope of the SPC incentive in relation to the significant field of research concerning new formulations. In the 7 years since the CJEU’s decision in Neurim, SPC applicants will have considered its scope and may have relied on its principles to invest in R&D and develop strategies to bring “different applications” of existing drugs to market – including, for example, based on new formulations (like Abraxis) and further therapeutic indications (e.g. via Type II variations). This decision means that a number of those strategies may need to be reconsidered. We will hopefully know more soon, including in in particular relating to how narrowly the principles in Neurim apply to the scenario where the same drug is developed for a new indication in the same species (humans) as there is another pending referral before the CJEU in Santen (C-673/18). So, as ever with SPCs, this remains an ongoing area to watch.

More within

Author

Dr Martin Turner

Head of Policy and Public Affairs

BIA

Martin joined the BIA in April 2016 as Policy and Projects Manager and was promoted to Head of Policy and Public Affairs in January 2019. He is responsible for the BIA's policy outputs and public affairs activities. He also leads on innovation and industrial strategy policy and provides the secretariat for the BIA’s Finance and Tax Advisory Committee and the Intellectual Property Advisory Committee.

Martin has eight years’ experience in policy and public affairs and has worked at the Royal Society, the Campaign for Science and Engineering, and the Association of Medical Research Charities. Before embarking on a career in policy, Martin completed a PhD in molecular biology at the University of Sheffield, where he also co-founded and was director of an award-winning science communication charity called Science Brainwaves. He has a BSc in molecular biology from the University of Manchester.